retatrutide phase 2 nejm 2023 obesity trial jastreboff vs Tirzepatide: Best Triple Agonist Guide 2026 Retatrutide Phase 2 NEJM Trial:

doi: 10.1016/j.neuroimage.2005.02.037 157 HartRPRoseCSHamerRM

The glucagon component is unique to retatrutide and increases energy expenditure through thermogenesis and fat breakdown, contributing an additional 2-3% weight loss beyond what tirzepatide achieves

May aid in repairing intestinal lining, beneficial for inflammatory bowel conditions 6

Peptide Vials (5 mg vial, 2.4 mg/week target) Each 5 mg vial covers about 2 weekly doses at 2.4 mg/week

At the end of the day, every individual is unique and different diets will provoke varying results in individuals, specifically in terms of food types, timing and macronutrient breakdowns